The signature and predictive value of immune parameters in patients with secondary hemophagocytic lymphohistiocytosis
Copyright © 2023 Elsevier GmbH. All rights reserved..
BACKGROUND: Secondary hemophagocytic lymphohistiocytosis (sHLH) is a rare but fatal clinical syndrome, characterized by severe immune dysfunction and overwhelming inflammatory response. However, the host immune signature and also its role in predicting the clinical outcome are not fully described.
OBJECTIVE: The present study aims to investigate the host immune status of sHLH patients in the early stage of the disease, including lymphocyte subsets, phenotypes and cytokines, and also to explore its clinical value in prognosis.
METHODS: Sixty-four patients with sHLH admitted to a tertiary hospital in central China between 2018 and 2022 were enrolled, of which 21 were deceased. The subsets and phenotypes of lymphocytes, and the levels of cytokines in serum were analyzed.
RESULTS: In patients with sHLH, the percentages of total T cells, CD8+ T cells, HLA-DR+ T cells, HLA-DR+CD8+ T cells, CD45RO+CD4+ T cells, and the levels of IL-1β, IL-2R, IL-6, IL-8, IL-10 and TNF-α were significantly increased, while the percentages of CD4+ T cells, NK cells, CD45RA+CD4+ T cells, CD45RA+ regulatory T (Treg) cells, the counts of total T cells, total B cells, CD4+ T cells, CD8+ T cells, NK cells, and the ratio of CD4+ T/CD8+ T cells were significantly decreased, compared with healthy controls (HC). In addition, dysregulation of host immune response and high inflammatory status were more obvious in deceased patients than that of survivors. Kaplan-Meier survival analysis and multivariate logistic regression analysis demonstrated that lower levels of CD4+ T cells count and CD28+CD4+ T cells percentage, but higher levels of NK cells percentage and IL-1β were poor prognostic indicators of sHLH.
CONCLUSION: The evaluation of immunological markers has critical value for selecting prognostic markers and potential treatment target among adults with sHLH.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:228 |
|---|---|
| Enthalten in: |
Immunobiology - 228(2023), 6 vom: 11. Nov., Seite 152759 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bai, Huan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cytokine |
|---|
| Anmerkungen: |
Date Completed 16.12.2023 Date Revised 09.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.imbio.2023.152759 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364313781 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364313781 | ||
| 003 | DE-627 | ||
| 005 | 20240209231949.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.imbio.2023.152759 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1285.xml |
| 035 | |a (DE-627)NLM364313781 | ||
| 035 | |a (NLM)37939638 | ||
| 035 | |a (PII)S0171-2985(23)04561-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bai, Huan |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The signature and predictive value of immune parameters in patients with secondary hemophagocytic lymphohistiocytosis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2023 | ||
| 500 | |a Date Revised 09.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier GmbH. All rights reserved. | ||
| 520 | |a BACKGROUND: Secondary hemophagocytic lymphohistiocytosis (sHLH) is a rare but fatal clinical syndrome, characterized by severe immune dysfunction and overwhelming inflammatory response. However, the host immune signature and also its role in predicting the clinical outcome are not fully described | ||
| 520 | |a OBJECTIVE: The present study aims to investigate the host immune status of sHLH patients in the early stage of the disease, including lymphocyte subsets, phenotypes and cytokines, and also to explore its clinical value in prognosis | ||
| 520 | |a METHODS: Sixty-four patients with sHLH admitted to a tertiary hospital in central China between 2018 and 2022 were enrolled, of which 21 were deceased. The subsets and phenotypes of lymphocytes, and the levels of cytokines in serum were analyzed | ||
| 520 | |a RESULTS: In patients with sHLH, the percentages of total T cells, CD8+ T cells, HLA-DR+ T cells, HLA-DR+CD8+ T cells, CD45RO+CD4+ T cells, and the levels of IL-1β, IL-2R, IL-6, IL-8, IL-10 and TNF-α were significantly increased, while the percentages of CD4+ T cells, NK cells, CD45RA+CD4+ T cells, CD45RA+ regulatory T (Treg) cells, the counts of total T cells, total B cells, CD4+ T cells, CD8+ T cells, NK cells, and the ratio of CD4+ T/CD8+ T cells were significantly decreased, compared with healthy controls (HC). In addition, dysregulation of host immune response and high inflammatory status were more obvious in deceased patients than that of survivors. Kaplan-Meier survival analysis and multivariate logistic regression analysis demonstrated that lower levels of CD4+ T cells count and CD28+CD4+ T cells percentage, but higher levels of NK cells percentage and IL-1β were poor prognostic indicators of sHLH | ||
| 520 | |a CONCLUSION: The evaluation of immunological markers has critical value for selecting prognostic markers and potential treatment target among adults with sHLH | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cytokine | |
| 650 | 4 | |a Hemophagocytic lymphohistiocytosis | |
| 650 | 4 | |a Lymphocyte phenotype | |
| 650 | 4 | |a Lymphocyte subset | |
| 650 | 4 | |a Prognosis | |
| 650 | 7 | |a HLA-DR Antigens |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Leukocyte Common Antigens |2 NLM | |
| 650 | 7 | |a EC 3.1.3.48 |2 NLM | |
| 700 | 1 | |a Wang, Yun |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Guoxing |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Ziyong |e verfasserin |4 aut | |
| 700 | 1 | |a Hou, Hongyan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Immunobiology |d 1985 |g 228(2023), 6 vom: 11. Nov., Seite 152759 |w (DE-627)NLM000456020 |x 1878-3279 |7 nnns |
| 773 | 1 | 8 | |g volume:228 |g year:2023 |g number:6 |g day:11 |g month:11 |g pages:152759 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.imbio.2023.152759 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 228 |j 2023 |e 6 |b 11 |c 11 |h 152759 | ||